Molecular analysis of tumours from the patients included in the SSG XVIII study which compared 1 versus 3 years of adjuvant imatinib showed that the largest benefit was observed in those patients with otherwise poor prognosis, i.e. those with KIT exon 11 deletions or insertion/deletions, (indels). This evidence concerns the gene KIT and neoplasm.